Posted by Michael Wonder on 04 Nov 2020
NICE publishes first technology assessment guidance for oesophageal cancer
4 November 2020 - NICE publishes more guidance on the use of nivolumab.
Nivolumab is not recommended, within its anticipated marketing authorisation, for the treatment of adults with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma after the use of fluoropyrimidine and platinum-based therapy.
Clinical trial evidence suggests nivolumab does not improve how well the disease responds or how long people live without their disease progressing compared with taxane treatment.
